Symptom-based pharmacotherapy for neuropathic pain related to spinal disorders: results from a patient-based assessment

• Published in: Scientific reports 2022-05, Vol.12 (1), p.7192-7192, Article 7192
• Main Authors: Nakajima, Hideaki, Watanabe, Shuji, Honjoh, Kazuya, Kubota, Arisa, Matsumine, Akihiko
• Format: Article
• Language: English
• Subjects: 692/1537/805; 692/308/409; 692/699/375; 692/700/155; 692/700/565; Analgesics; Analgesics - therapeutic use; Cauda Equina Syndrome; Drug development; Drug therapy; Duloxetine; Duloxetine Hydrochloride; Humanities and Social Sciences; Humans; Mental disorders; multidisciplinary; Musculoskeletal Pain - drug therapy; Neuralgia; Neuralgia - diagnosis; Neuralgia - drug therapy; Neuralgia - etiology; Pain; Pain Measurement; Paresthesia; Patients; Phenotypes; Retrospective Studies; Science; Science (multidisciplinary); Spinal cord; Spinal Diseases
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-11345-y

Existing guidelines advocate an updated therapeutic algorithm for chronic neuropathic pain (NeP), but pharmacotherapeutic management should be individualized to pain phenotypes to achieve higher efficacy. This study was aimed to evaluate the efficacy of medications, based on NeP phenotypes, and to propose symptom-based pharmacotherapy. This retrospective study was enrolled 265 outpatients with chronic NeP related to spinal disorders. The patients were classified into three groups: spinal cord-related pain, radicular pain, and cauda equina syndrome. Data were obtained from patient-based questionnaires using Neuropathic Pain Symptom Inventory (NPSI) and the Brief Scale for Psychiatric Problems in Orthopaedic Patients, and from clinical information. The proportions of patients with ≥ 30% and ≥ 50% reduction in NPSI score for each pain subtype (spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia) and drugs were evaluated. The pain reduction rate was significantly lower in patients with spinal cord-related pain, especially for paresthesia/dysesthesia. For spinal cord-related pain, duloxetine and neurotropin had insufficient analgesic effects, whereas mirogabalin was the most effective. Pregabalin or mirogabalin for radicular pain and duloxetine for cauda equina syndrome are recommended in cases of insufficient analgesic effects with neurotropin. The findings could contribute to better strategies for symptom-based pharmacotherapeutic management.